These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9280876)

  • 1. [Late onset type I tyrosinemia].
    Klujber V; Sallai A; Kálmánchey R; Szönyi L; Hosszú E
    Orv Hetil; 1997 Jul; 138(28):1805-8. PubMed ID: 9280876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising new treatment for type I tyrosinemia.
    Heubi JE
    J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
    [No Abstract]   [Full Text] [Related]  

  • 3. NTBC as palliative treatment in chronic tyrosinaemia type I.
    Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
    J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
    [No Abstract]   [Full Text] [Related]  

  • 4. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
    Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
    Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
    Bird S; Miller NJ; Collins JE; Rice-Evans CA
    J Inherit Metab Dis; 1995; 18(2):123-6. PubMed ID: 7564225
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
    J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
    Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
    Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
    Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment for tyrosinaemia.
    Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E; Lindstedt S
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
    Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontransplant treatment of tyrosinemia.
    Holme E; Lindstedt S
    Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosinemia: the Quebec experience.
    Paradis K
    Clin Invest Med; 1996 Oct; 19(5):311-6. PubMed ID: 8889268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
    Äärelä L; Nevalainen PI; Kurppa K; Hiltunen P
    J Pediatr Endocrinol Metab; 2020 May; 33(5):661-664. PubMed ID: 32238608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
    Grompe M; Lindstedt S; al-Dhalimy M; Kennaway NG; Papaconstantinou J; Torres-Ramos CA; Ou CN; Finegold M
    Nat Genet; 1995 Aug; 10(4):453-60. PubMed ID: 7545495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of seven patients with hereditary tyrosinemia type 1.
    Gokay S; Ustkoyuncu PS; Kardas F; Kendirci M
    J Pediatr Endocrinol Metab; 2016 Oct; 29(10):1151-1157. PubMed ID: 27682708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.